- Poster presentation
- Open Access
PReS-FINAL-2280: Lupus disease activity in a pediatric Colombian cohort with systemic lupus erytematosus
© Diaz Maldonado et al.; licensee BioMed Central Ltd. 2013
- Published: 5 December 2013
- Systemic Lupus Erythematosus
- Pediatric Patient
- Pediatric Population
- Parametric Test
- Descriptive Study
Systemic Lupus Erythematosus (SLE) is disease which may have severe and variable activity in the pediatric population.
compare the index of activity in two times at cohort of pediatric patients with SLE.
Analytic descriptive study. 89 patients with diagnosis SLE (1986 ACR criteria) from a rheumatology center at a pediatric hospital were evaluated at the time of diagnosis and twelve months after. Medical records were reviewed registering the following variables: score SLEDAI, Antinuclear antibodies (ANAs), Anti-DNA antibodies and complement C3 and C4 levels. Analysis was done through parametric and non parametric tests to compare means and proportions using STATA11. Shapiro-Wilk and Wilcoxon tests (non-normally distributed data) were applied.
Median score SLEDAI at the time of diagnosis was 23 (min 4 max 61); after 12 months it was 4 (min 0 max 31) (p = 0.001). Antinuclear antibodies (ANAs) reactivity at the diagnosis was 88,1%; after 12 months it was 6,67% (p = 0.17). Anti-DNA antibodies reactivity at the diagnosis was 66,7%; after 12 months it was 56,41% (p = 0.01). C3 level was diminished in 67,95% of patients at the diagnosis; after 12 months it was diminished in 33,3% of patients (p = 0.01). C4 level was diminished in 71,7% of patients at the diagnosis; after 12 months it was diminished in 40% of patients (p = 0.01).
Statistical significance was documented regarding score SLEDAI, Anti-DNA antibodies reactivity, hypocomplementemia for the time of diagnosis and twelve month follow-up. This suggests that improvement in disease activity was due to the established treatment.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.